Market Intelligence, Clinical Progress, and High-Purity Reagents for Molecular Glue Degrader Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for C19orf72/DCAF15 molecular glue discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | DCAF15 (C19orf72) Recombinant Protein Full-length WD40 domain. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 or E. coli expression. |
View DCAF15 Products |
| Antigen (Mutant) | DCAF15 Resistance Mutants (W105A, D147Y, D107A) Clinically relevant mutations for SAR studies. Sequence Verified. |
View DCAF15 Products |
| Substrate (RBM39) | RBM39 (S56) Recombinant Protein Full-length or RRM domains. High purity (>95%). |
View RBM39 Products |
| Complex Partner: DDB1 | DDB1 Recombinant Protein CRL4 adaptor protein. Required for functional DCAF15 complex assembly. |
View DDB1 Products |
| Complex Partner: CUL4B | CUL4B Recombinant Protein E3 ligase cullin backbone for in vitro ubiquitination cascade studies. |
View CUL4B Products |
| Gene Delivery | DCAF15 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. CMV promoter. Puromycin selectable. |
View DCAF15 Products |
| Detection Control | Anti-RBM39 Antibody Recombinant rabbit monoclonal for degradation validation (Western/HiBiT). |
View RBM39 Products |
| Validator | DCAF15 siRNA Set For knockdown verification and specificity controls. Three target-specific sequences. |
View DCAF15 Products |
| Related Target: RBM23 | RBM23 Recombinant Protein Secondary neo-substrate; assess selectivity vs. RBM39. |
View RBM23 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Formation (DCAF15-DDB1-Glue-RBM39) | Human DCAF15 & RBM39 proteins co-expressed with matching lot numbers. Sequence Verified, >95% purity. HEK293-expressed DCAF15 with native eukaryotic folding. Suitable for SPR/BLI ternary assembly. |
| Resistance Mutation Screening | Pre-validated W105A, D147Y, D107A mutants. Sequence Verified. Same buffer/conditions as WT for direct comparative SPR. |
| Selectivity vs. DCAF Family (DCAF1-17) | Homology-aware antigen design. High purity WT DCAF15 for cross-screening panels against paralogs. Sequence-verified homolog panel proteins for subfamily counter-screening. |
| Cross-Species Preclinical Translation | Human / Mouse / Cyno ortholog proteins available with >95% purity and sequence verification. |
| Cellular Degradation Validation | DCAF15 ORF Lentivirus for stable overexpression in HiBiT reporter cell lines. Endotoxin controlled. |
| Lack of Biochemical Controls | Matching WT and Mutant proteins from identical expression systems (batch consistency guaranteed). |
Live C19orf72/DCAF15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Indisulam Clinical Trials
- ➤ View Tasisulam Clinical Trials
- ➤ Latest Resistance Research (DCAF15 Mutations)
- ➤ RBM39 Degradation Mechanism Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for C19orf72/DCAF15-targeted molecular glues is shifting from first-generation aryl sulfonamides (Indisulam, Tasisulam) to next-generation scaffolds with improved selectivity and reduced clinical toxicity. As the field validates DCAF15 as a druggable E3 ligase substrate receptor, the next wave of R&D is targeting resistance mutations (W105 hotspot, D147, D107) and expanding the substrate scope beyond RBM39/RBM23 to novel neo-substrates. The emergence of DCAF15 as a key component of the CRL4 complex positions it as a critical node for targeted protein degradation (TPD) strategies in solid tumors and hematologic malignancies. Combination strategies with spliceosome inhibitors and DNA-damage response inhibitors are being actively explored.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue (1st Gen) | Eisai (Indisulam), Novartis (Tasisulam), Crew Bio, Proxygen | AML, Breast Cancer, Solid Tumors | Ternary Complex SPR & Ubiquitination Assays (WT/Mutant DCAF15 + RBM39) |
| Next-Gen Molecular Glue | BioTheryX, CytosX, Emerging Pharma | Refractory Cancers | Resistance Mutant Panel Screening (W105A/D147Y/D107A) |
| Chemical Probe (Tool Compound) | Structural Genomics Consortium (SGC) | Target Validation | Co-crystallization Grade Proteins (High purity, native folding) |
| Targeted Protein Degradation Platform | Biotech Innovators (e.g., Kymera, C4 Therapeutics) | Splicing-Driven Cancers | Cellular Degradation Reporter (Lentivirus & siRNA controls) |